[ Ссылка ]
Within the past 2 years, interest in investigator-initiated clinical trials has increased greatly. The additional proof of practice and clinical application data that these types of trials provide have allowed for the transition of many newly approved therapies to standard practice. While research offices are doing their best to support these endeavors, the additional administrative responsibilities involved are often unfamiliar, as they are normally taken on by industry sponsors and outside governmental agencies. Consequently, mistakes made during the initial development and start-up stages of these trials are causing institutions significant financial and compliance-related ramifications. Join Clinical Research Analyst Liz Christianson as she discusses how to overcome these start-up struggles and oversights of investigator-initiated trials.
